The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioventix Share News (BVXP)

Share Price Information for Bioventix (BVXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,375.00
Bid: 4,300.00
Ask: 4,450.00
Change: 0.00 (0.00%)
Spread: 150.00 (3.488%)
Open: 4,375.00
High: 4,380.00
Low: 4,375.00
Prev. Close: 4,375.00
BVXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: Belvoir ups yearly payout; SigmaRoc swings to profit

Mon, 27th Mar 2023 15:01

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday not separately reported by Alliance News.

---------

Belvoir Group PLC - Lincolnshire, England-based property franchise and financial services - Posts revenue of GBP33.7 million for 2022, up 14% from GBP29.6 million in 2021. Revenue from the financial services division increases by 26% to GBP18.1 million, from GBP14.4 million a year earlier. Pretax profit drops slightly to GBP9.1 million from GBP9.3 million, as administrative costs rise by 16% to GBP11.2 million from GBP9.7 million a year earlier. Declares a final dividend of 5.0 pence per share, up 11% from 4.5p a year earlier. This takes the total dividend for 2022 to 9.0p per share, up 5.9% from 8.5p a year prior. Looking ahead, says remains confident that it will perform well against the market in 2023 and beyond.

----------

SigmaRoc PLC - quarried materials company - Says revenue for 2022 is GBP538.0 million, up 98% from GBP272.0 million in 2021. Swings to a pretax profit of GBP42.7 million from a loss of GBP2.3 million, as profit from operations surges to GBP115.9 million from GBP61.9 million a year earlier. Earnings before interest, tax, depreciation and amortisation amount to GBP101.7 million, up from GBP49.3 million in 2021. Earnings per share total 8.0 pence per share, up from 5.4p in 2021. Chief Executive Officer Max Vermorken says the group has delivered performance well ahead of expectations in 2022, and that the start of 2023 has been encouraging.

----------

Plexus Holdings PLC - West Sussex-based engineering services provider - For the six months ended on December 31, sales revenue is GBP709,000, down from GBP734,000 a year before. Pretax loss widens to GBP2.1 million from GBP1.9 million, as administrative expenses increase to GBP2.6 million from GBP2.5 million in 2021. Says the loss comes after absorbing depreciation and amortisation costs of about GBP800,000. Chief Executive Ben van Bilderbeek says: "While the first half of this financial year continued to be challenging with low sales revenue and trading losses, I am encouraged by a number of positive internal and external indicators and developments." Looking ahead, Plexus warns of headwinds in Europe and UK, but says that the global wellhead equipment market is now beginning to thrive, which it says can be positive for the firm.

----------

Northamber PLC - London-based distributor of audio-visual and information technology equipment - Posts revenue of GBP33.6 million for the six months ended on December 31, up 4.1% from GBP32.3 million a year before. However, pretax loss widens to GBP250,000 from GBP116,000, as administrative costs increase to GBP1.8 million from GBP1.6 million a year earlier. Declares an interim dividend of 0.3 pence per share. Looking ahead, Northamber says it remains cautiously optimistic that the investments it has made in supporting its partners will "continue to drive growth of strategic business units although some of these investments returns have been hampered by the impact of inflationary issues".

----------

Bioventix PLC - London-based biotechnology company - Says revenue for 2022 increases by 25% to GBP5.9 million from GBP4.7 million in 2021. Says sales of physical product have performed well, and revenue from its vitamin D antibody and other core antibodies have all increased as anticipated. Pretax profit climbs by 27% to GBP4.5 million from GBP3.6 million, as operating profit grows to GBP4.5 million from GBP3.6 million a year earlier. Declares interim dividend of 62 pence per share, up 20% from 52p a year prior. Looking ahead, says it remains optimistic about its troponin revenue and looks forward to reporting further progress in the second half of the year.

---------

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
8 Oct 2018 12:09

Bioventix posts healthy profits, ups dividend; warns of plateauing vit-D sales

(Sharecast News) - Aim's Bioventix announced Monday it would pay a special dividend after a strong year of revenue and profit growth - but also sounded a warning over one of its key revenue streams.

Read more
26 Mar 2018 10:44

Bioventix Lifts Interim Dividend 25% After Strong Revenue Growth

LONDON (Alliance News) - Medical technology company Bioventix PLC on Monday said it saw an increase in revenue and profit in the first half of its financial year, due to a by

Read more
22 Aug 2016 09:34

Bioventix profits will beat forecasts, boost eyed from Siemens link

(ShareCast News) - Bioventix revealed that revenues and profits will be ahead of expectations for the full year thanks to currency effects and continued demand for its monoclonal antibodies. Revenue for the year to 30 June will come in at £5.3m, which is at least 11% ahead of the forecast £4.8m and

Read more
31 May 2016 09:27

Bioventix Signs Antibodies Deal With Norway-Based Pre Diagnostics

Read more
21 Mar 2016 10:08

Bioventix Hikes Dividend As Profit And Sales Increase In First Half

Read more
14 Jan 2016 10:08

Bioventix To Take 10% Stake As It Teams Up With Norwegian Start-up

Read more
25 Nov 2015 16:14

AGM, EGM Calendar - Week Ahead

Read more
5 Oct 2015 07:54

Bioventix Optimistic For Further Growth As Annual Profit Rises

Read more
4 Sep 2015 07:17

LONDON BRIEFING: Bwin.Party Chooses GVC's Takeover Offer Over 888's

Read more
4 Sep 2015 06:32

Bioventix Annual Profit To "Significantly" Beat Market Expectations

Read more
30 Mar 2015 10:15

Bioventix Profit Up, Optimistic On Vitamin D Antibody Product

Read more
7 Oct 2014 08:34

Bioventix Raises Total Dividend 66% As Full-Year Profit Rises

Read more
21 Aug 2014 09:44

Bioventix signs deal to end dispute with Diasource

Bioventix, an AIM-listed company focused on the development of anti-bodies, has signed an agreement to license intellectual property owned by Belgian company Diasource ImmunoAssays. The two groups had been in dispute over one of Diasource's European patents, but said a licence agreement was "the pr

Read more
21 Aug 2014 09:41

Bioventix Signs Licence Deal With DIAsource Over Test Patent

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.